摘要
目的:探讨四子温肺汤对哮喘-慢阻肺重叠综合征(Asthma-COPD overlap syndrome,ACOS)急性期寒痰郁肺夹瘀证患者肺功能、炎症因子水平及临床疗效的影响。方法:将88例ACOS患者按照治疗方案不同分为对照组和观察组,每组44例。对照组采用布地奈德福莫特罗吸入粉雾剂(Ⅱ)联合噻托溴铵吸入粉雾剂进行治疗,而观察组则在对照组治疗方案的基础上,联合给予四子温肺汤治疗。两组均连续治疗10天。比较两组治疗前后肺功能指标,血清炎性因子[超敏C反应蛋白(hypersensitive C-reactive protein,hs-CRP)、白细胞介素17(interleukin,IL-17)、白细胞介素4(interleukin,IL-4)]水平、哮喘控制测试(asthma control test,ACT)评分、慢性阻塞性肺疾病评估测试(COPD assessment test,CAT)评分和临床疗效、不良反应发生情况。结果:治疗后两组用力肺活量(forced vital capacity,FVC)、第1秒用力呼气容积(forced expiratory volume in one second,FEV1)、FEV1/FVC与呼气流量峰值(peak expiratory flow,PEF)均较治疗前升高(P<0.05),血清炎症因子水平、CAT评分均较治疗前降低(P<0.05),ACT评分增加(P<0.05);且上述指标观察组与对照组比较,差异均有统计学意义(P<0.05)。观察组总有效率[97.72%(43/44)]高于对照组[90.91%(40/44)](P<0.05);两组不良反应发生率无明显差异(P>0.05)。结论:四子温肺汤治疗ACOS寒痰郁肺夹瘀证患者,能改善患者肺功能,控制哮喘症状,降低血清炎性反应,提高临床疗效。
Objective:To explore the influence of Sizi Wenfei decoction(four-seeds warming-lung decoction)on lung function,and the levels of inflammatory factors and clinical effects of patients with acute asthma-COPD overlap syndrome(ACOS)of cold phlegm obstructing lung and blood stasis pattern.Methods:All 88 ACOS patients were divided into the control group and the observation group according to therapeutic regimen,44 cases in each group.The control group was treated with Budesneide formoterol inhalation powderⅡand tiotropium inhalation powder,and Sizi Wenfei decoction was given to the observation group,and both groups were treated for ten days continuously.To compare the indexes of lung function,the levels of serum inflammatory factors including hs-CRP,IL-17 and IL-4,and ACT scores,CAT scores,clinical effects and the incidences of adverse reaction before and after the treatment in the two groups.Results:After the treatment,FEV1,FVC,FEV1/FVC and PEF were elevated than before the treatment(P<0.05),the levels of serum inflammatory factors and CAT scores were reduced than before the treatment(P<0.05),ACT scores were increased(P<0.05);and the difference had statistical meaning in the above indexes between the observation group and the control group(P<0.05).Total effective rate of the observation group was[97.72%(43/44)],higher than[90.91%(40/44)]of the control group(P<0.05);there was no significant difference in the incidences of adverse reaction between both groups(P>0.05).Conclusion:Sizi Wenfei decoction in the treatment of ACOS of cold phlegm obstructing lung and blood stasis pattern could improve lung function,control asthma symptoms,reduce serum inflammatory reaction and raise clinical effects.
作者
李淑玲
程立军
马定勤
王晓彬
豆根龙
孔德云
罗海霞
王兴茂
LI Shuling;CHENG Lijun;MA Dingqin;WANG Xiaobin;DOU Genlong;KONG Deyun;LUO Haixia;WANG Xingmao(Gansu Provincial Hospital of Traditional Chinese Medicine,Lanzhou 730050,China;Gansu Provincial Academy of Chinese Medicine,Lanzhou 730050,China;Kangtai Hospital,Lanzhou 730046,China;Yongjing County Hospital of Traditional Chinese Medicine,Yongjing 731600,China)
出处
《西部中医药》
2024年第11期124-128,共5页
Western Journal of Traditional Chinese Medicine
基金
国家中医药管理局“十二五”重点学科中医文化学建设项目(国中医药教育便函〔2012〕170号)
甘肃省中医药重点专科中医药信息学建设项目(甘中卫函〔2013〕462号)。
关键词
哮喘-慢阻肺重叠综合征
急性期
寒痰郁肺夹瘀证
肺功能
炎症因子
临床疗效
asthma-COPD overlap syndrome,acute stage
cold phlegm obstructing lung and blood stasis pattern
lung function
inflammatory factors
clinical effects
